Can I increase the dose of gliclazide (a sulfonylurea) in a patient with impaired renal function (GFR of 58) who is currently taking 60mg of gliclazide MR (modified release)?

Can You Increase Gliclazide MR Dose at GFR 58?

Yes, you can safely increase the dose of gliclazide MR in this patient with a GFR of 58 mL/min/1.73 m², as gliclazide does not require dose adjustment until GFR falls below 30 mL/min/1.73 m². 1

Renal Safety Profile of Gliclazide

• Gliclazide is primarily hepatically metabolized, with only 4% of total drug clearance occurring through renal excretion, making it one of the safer sulfonylureas in renal impairment 2
• At GFR 58 mL/min/1.73 m² (CKD stage G3a), no dose adjustment is required for gliclazide 1
• Dose reduction or caution is only recommended when GFR falls below 30 mL/min/1.73 m² 1

Dosing Considerations for Gliclazide MR

• The maximum recommended dose for gliclazide MR is 120 mg once daily 3
• Recent pharmacometric modeling suggests the MR formulation may be increased up to 270 mg for optimal efficacy without exceeding hypoglycemia risk, though this exceeds current standard recommendations 4
• Your patient is currently on 60 mg MR, which is half the standard maximum dose, leaving room for dose escalation 3
• The MR formulation provides 24-hour glycemic control with once-daily dosing and shows high bioavailability unaffected by food 3

Important Caveats Before Dose Escalation

However, before increasing the gliclazide dose, you should strongly consider whether this patient needs an SGLT2 inhibitor instead, as current guidelines prioritize these agents for kidney and cardiovascular protection in patients with GFR <60 mL/min/1.73 m² 5

• KDIGO 2020 guidelines give a Grade 1A recommendation for SGLT2 inhibitors in patients with type 2 diabetes and eGFR ≥30 mL/min/1.73 m² for cardiovascular and kidney benefits 5
• If adding an SGLT2 inhibitor, you may need to reduce or discontinue the sulfonylurea to prevent hypoglycemia 5
• GLP-1 receptor agonists (liraglutide, dulaglutide, semaglutide) require no dose adjustment at this GFR and carry lower hypoglycemia risk than sulfonylureas 6, 1

Monitoring Requirements

• Monitor renal function at least every 3-6 months when GFR is between 45-59 mL/min/1.73 m² 5
• If the patient is also on metformin, continue current dose but increase monitoring frequency 5
• Watch for hypoglycemia, though gliclazide has a lower incidence compared to other sulfonylureas due to its specific effect on first-phase insulin release 7

Clinical Algorithm

If glycemic control is inadequate on current therapy:

1. First priority: Add an SGLT2 inhibitor for kidney/CV protection (may require reducing gliclazide) 5
2. Second option: Add a GLP-1 receptor agonist if SGLT2i contraindicated 6
3. Third option: Increase gliclazide MR to 90-120 mg once daily if above agents are not suitable 3

The renal impairment itself is not a barrier to increasing gliclazide at GFR 58, but modern diabetes management in CKD prioritizes agents with proven kidney and cardiovascular benefits over simply escalating sulfonylurea doses 5